

NeurAxon, Inc. to Present at BIO International Convention June 18, 2008

WALTHAM, MA. June 17, 2008 – NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer, will present at the 2008 BIO International Convention taking place June 17-20, 2008 in San Diego, CA.

The NeurAxon presentation will be delivered on Wednesday, June 18, 2008 at 3:30pm Pacific Time in Room 4 at the San Diego Convention Center.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT antagonist which is currently in Phase 2 trials for acute migraine.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Contact:

Chris Erdman
MacDougall Biomedical Communications
781-235-3060, ext. 14